145 episodes

BioCentury's streaming commentary on biotech industry trends, plus interviews with leading KOLs. For over 28 years, BioCentury has given biopharma executives, investors and institutions the power to make business-critical decisions through independent, deep-dive analysis; high-quality data; industry-leading business intelligence; and global conferences.

BioCentury This Week BioCentury

    • Science
    • 3.0 • 2 Ratings

BioCentury's streaming commentary on biotech industry trends, plus interviews with leading KOLs. For over 28 years, BioCentury has given biopharma executives, investors and institutions the power to make business-critical decisions through independent, deep-dive analysis; high-quality data; industry-leading business intelligence; and global conferences.

    Ep. 138 - FDA User Fee Endgame, East-West Summit & Biogen

    Ep. 138 - FDA User Fee Endgame, East-West Summit & Biogen

    Everything’s at stake for FDA as user fee legislation approaches a critical deadline this week, Washington Editor Steve Usdin says on the latest episode of BioCentury This Week. Usdin details the next steps in the process, which FDA reforms are being dropped from the “clean” user fee bill and the future of healthcare legislation. BioCentury’s editorial team also recaps the top takeaways from Global Blood Therapeutics CEO Ted Love’s appearance on The BioCentury Show, previews the upcoming BioCentury-BayHelix East-West Biopharma Summit and assesses two upcoming milestones for Biogen: an FDA decision on tofersen for amyotrophic lateral sclerosis and Phase III data for Alzheimer’s therapy lecanemab that’s due from partner Eisai.

    • 27 min
    Ep. 137 - Intellia's Data, IRA's Orphan Impact, CFIUS Order

    Ep. 137 - Intellia's Data, IRA's Orphan Impact, CFIUS Order

    A year after it reported its first clinical data showing CRISPR-based gene editing may live up to its promise, Intellia has provided evidence for the second time that its platform can knock down a clinically relevant target in the liver, and revealed the first data showing it can deliver clinical benefit. On the latest BioCentury This Week podcast, BioCentury's editors discuss the hereditary angioedema data for NTLA-2002. They also explain why the Inflation Reduction Act could have an outsized effect on the development of orphan drugs and how an Executive Order related to the Committee on Foreign Investment in the United States (CFIUS) signed by President Joe Biden singles out biotech and biomanufacturing for intensified foreign investment scrutiny.

    • 18 min
    Ep. 136 - IRA, KRAS & ESMO

    Ep. 136 - IRA, KRAS & ESMO

    Biopharma executives and investors are bracing for the impact of the newly passed Inflation Reduction Act. On the latest BioCentury This Week podcast, BioCentury's editors discuss pharma CEOs’ warnings that the law will reduce incentives for small molecule drug development, how biotech VCs may adjust deployment of their funds and how the government could implement the law.Turning to readouts from the European Society of Medical Oncology Congress, the BioCentury podcast team explains why the latest data for Amgen's Lumakras could shake up the KRAS inhibitor race and how Chinese investigator-initiated trials are accelerating CAR T innovation.

    • 22 min
    Ep 135 Pt. 5 - A Portrait of Biopharma's New Leaders

    Ep 135 Pt. 5 - A Portrait of Biopharma's New Leaders

    Digital fluency, the imperative to have an impact on society and an eagerness to make change now, not in future decades, mark the future leaders of the industry, says BioCentury Editor in Chief Simone Fishburn. On the fifth and concluding BioCentury This Week podcast accompanying Back to School 2022, Fishburn and BioCentury’s editorial team discuss the defining traits of industry’s incoming generation of leaders and the evolving skills required for the future of biotech. Access all of BioCentury's Back to School content here.

    https://www.biocentury.com/topics/back-to-school-auth 

    • 19 min
    Ep 135 Pt. 4 - Filling Biopharma's Talent Pipeline

    Ep 135 Pt. 4 - Filling Biopharma's Talent Pipeline

    The need to recruit and train regulators is acute in developed as well as low- and middle-income countries, BioCentury Washington Editor Steve Usdin says. On the fourth of five BioCentury This Week podcasts accompanying Back to School 2022, Usdin and BioCentury’s editorial team discuss how drawing top talent means agencies must persuade candidates that careers are infused with purpose and support a vital mission. BioCentury Senior Editor Karen Tkach Tuzman says biopharma companies, facing their own talent crunch, will benefit from making themselves more visible, accessible and instructive to new entrants. Access all of BioCentury's Back to School content here.

    https://www.biocentury.com/topics/back-to-school-auth 

    • 16 min
    Ep 135 Pt. 3 - Rising Leaders & the VC View on Talent

    Ep 135 Pt. 3 - Rising Leaders & the VC View on Talent

    Solving the biopharma industry’s management crunch will require today’s leaders to open their networks, and provide more leadership opportunities and mentoring to rising leaders, says BioCentury Editor in Chief Simone Fishburn. On the third of five BioCentury This Week podcasts accompanying Back to School 2022, Fishburn and BioCentury’s editorial team discuss the group of employees who see the C-suite as their next step, why they want to get there and the impediments they must overcome. BioCentury’s editors also assess how VCs are building boards to guide first-time CEOs, and discuss concerns that the increase in compensation across the biopharma sector has gotten out of hand. Access all of BioCentury's Back to School content here.

    https://www.biocentury.com/topics/back-to-school-auth

    • 16 min

Customer Reviews

3.0 out of 5
2 Ratings

2 Ratings

You Might Also Like

STAT
Timmerman Report
Biotech 2050
Matt Pillar
The Bio Report
ARK Invest